Skip to main content
Top
Published in: Discover Oncology 1/2024

Open Access 01-12-2024 | Prostate Cancer | Research

Prediction of prostate cancer aggressiveness using magnetic resonance imaging radiomics: a dual-center study

Authors: Nini Pan, Liuyan Shi, Diliang He, Jianxin Zhao, Lianqiu Xiong, Lili Ma, Jing Li, Kai Ai, Lianping Zhao, Gang Huang

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Purpose

The Gleason score (GS) and positive needles are crucial aggressive indicators of prostate cancer (PCa). This study aimed to investigate the usefulness of magnetic resonance imaging (MRI) radiomics models in predicting GS and positive needles of systematic biopsy in PCa.

Material and Methods

A total of 218 patients with pathologically proven PCa were retrospectively recruited from 2 centers. Small-field-of-view high-resolution T2-weighted imaging and post-contrast delayed sequences were selected to extract radiomics features. Then, analysis of variance and recursive feature elimination were applied to remove redundant features. Radiomics models for predicting GS and positive needles were constructed based on MRI and various classifiers, including support vector machine, linear discriminant analysis, logistic regression (LR), and LR using the least absolute shrinkage and selection operator. The models were evaluated with the area under the curve (AUC) of the receiver-operating characteristic.

Results

The 11 features were chosen as the primary feature subset for the GS prediction, whereas the 5 features were chosen for positive needle prediction. LR was chosen as classifier to construct the radiomics models. For GS prediction, the AUC of the radiomics models was 0.811, 0.814, and 0.717 in the training, internal validation, and external validation sets, respectively. For positive needle prediction, the AUC was 0.806, 0.811, and 0.791 in the training, internal validation, and external validation sets, respectively.

Conclusions

MRI radiomics models are suitable for predicting GS and positive needles of systematic biopsy in PCa. The models can be used to identify aggressive PCa using a noninvasive, repeatable, and accurate diagnostic method.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Wright JL, Salinas CA, Lin DW, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol. 2009;182:2702–7.CrossRefPubMedPubMedCentral Wright JL, Salinas CA, Lin DW, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol. 2009;182:2702–7.CrossRefPubMedPubMedCentral
4.
go back to reference Bertelli E, Mercatelli L, Marzi C, et al. Machine and deep learning prediction of prostate cancer aggressiveness using multiparametric MRI. Front Oncol. 2021;11: 802964.CrossRefPubMed Bertelli E, Mercatelli L, Marzi C, et al. Machine and deep learning prediction of prostate cancer aggressiveness using multiparametric MRI. Front Oncol. 2021;11: 802964.CrossRefPubMed
5.
go back to reference Hurwitz LM, Agalliu I, Albanes D, et al. Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research. J Natl Cancer Inst. 2021;113:727–34.CrossRefPubMed Hurwitz LM, Agalliu I, Albanes D, et al. Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research. J Natl Cancer Inst. 2021;113:727–34.CrossRefPubMed
7.
go back to reference Yang Y. Comments on National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version). Chinese J Cancer Res. 2022;34:456–7.CrossRef Yang Y. Comments on National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version). Chinese J Cancer Res. 2022;34:456–7.CrossRef
8.
go back to reference de Rooij M, Israël B, Tummers M, et al. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training. Eur Radiol. 2020;30:5404–16.CrossRefPubMedPubMedCentral de Rooij M, Israël B, Tummers M, et al. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training. Eur Radiol. 2020;30:5404–16.CrossRefPubMedPubMedCentral
9.
go back to reference Popiţa C, Popiţa AR, Andrei A, et al. Local staging of prostate cancer with multiparametric-MRI: accuracy and inter-reader agreement. Med Pharm Rep. 2020;93:150–61.PubMedPubMedCentral Popiţa C, Popiţa AR, Andrei A, et al. Local staging of prostate cancer with multiparametric-MRI: accuracy and inter-reader agreement. Med Pharm Rep. 2020;93:150–61.PubMedPubMedCentral
10.
go back to reference Gong L, Xu M, Fang M, et al. The potential of prostate gland radiomic features in identifying the Gleason score. Comput Biol Med. 2022;144: 105318.CrossRefPubMed Gong L, Xu M, Fang M, et al. The potential of prostate gland radiomic features in identifying the Gleason score. Comput Biol Med. 2022;144: 105318.CrossRefPubMed
11.
go back to reference Püllen L, Radtke JP, Wiesenfarth M, et al. External validation of novel magnetic resonance imaging-based models for prostate cancer prediction. BJU Int. 2020;125:407–16.CrossRefPubMed Püllen L, Radtke JP, Wiesenfarth M, et al. External validation of novel magnetic resonance imaging-based models for prostate cancer prediction. BJU Int. 2020;125:407–16.CrossRefPubMed
12.
go back to reference Ramtohul T, Djerroudi L, Lissavalid E, et al. Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers. Radiology. 2023;308: e222646.CrossRefPubMed Ramtohul T, Djerroudi L, Lissavalid E, et al. Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers. Radiology. 2023;308: e222646.CrossRefPubMed
13.
go back to reference Mayer R, Simone CB 2nd, Turkbey B, et al. Prostate tumor eccentricity predicts Gleason score better than prostate tumor volume. Quant Imaging Med Surg. 2022;12:1096–108.CrossRefPubMedPubMedCentral Mayer R, Simone CB 2nd, Turkbey B, et al. Prostate tumor eccentricity predicts Gleason score better than prostate tumor volume. Quant Imaging Med Surg. 2022;12:1096–108.CrossRefPubMedPubMedCentral
14.
go back to reference Jeon J, Olkhov-Mitsel E, Xie H, et al. Temporal stability and prognostic biomarker potential of the prostate cancer urine miRNA transcriptome. J Natl Cancer Inst. 2020;112:247–55.CrossRefPubMed Jeon J, Olkhov-Mitsel E, Xie H, et al. Temporal stability and prognostic biomarker potential of the prostate cancer urine miRNA transcriptome. J Natl Cancer Inst. 2020;112:247–55.CrossRefPubMed
15.
go back to reference Gong L, Xu M, Fang M, et al. Noninvasive prediction of high-grade prostate cancer via biparametric MRI radiomics. J Magnet Resonan Imaging JMRI. 2020;52:1102–9.CrossRef Gong L, Xu M, Fang M, et al. Noninvasive prediction of high-grade prostate cancer via biparametric MRI radiomics. J Magnet Resonan Imaging JMRI. 2020;52:1102–9.CrossRef
16.
go back to reference Zhang L, Jiang D, Chen C, et al. Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer. Br J Radiol. 2022;95:20210191.CrossRefPubMed Zhang L, Jiang D, Chen C, et al. Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer. Br J Radiol. 2022;95:20210191.CrossRefPubMed
17.
go back to reference De Visschere P, Lumen N, Ost P, et al. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA. Clin Radiol. 2017;72:23–32.CrossRefPubMed De Visschere P, Lumen N, Ost P, et al. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA. Clin Radiol. 2017;72:23–32.CrossRefPubMed
18.
go back to reference Fan X, Xie N, Chen J, et al. Multiparametric MRI and machine learning based radiomic models for preoperative prediction of multiple biological characteristics in prostate cancer. Front Oncol. 2022;12: 839621.CrossRefPubMedPubMedCentral Fan X, Xie N, Chen J, et al. Multiparametric MRI and machine learning based radiomic models for preoperative prediction of multiple biological characteristics in prostate cancer. Front Oncol. 2022;12: 839621.CrossRefPubMedPubMedCentral
20.
go back to reference Jing R, Wang J, Li J, et al. A wavelet features derived radiomics nomogram for prediction of malignant and benign early-stage lung nodules. Sci Rep. 2021;11:22330.CrossRefPubMedPubMedCentral Jing R, Wang J, Li J, et al. A wavelet features derived radiomics nomogram for prediction of malignant and benign early-stage lung nodules. Sci Rep. 2021;11:22330.CrossRefPubMedPubMedCentral
21.
go back to reference Zheng Y, Zhou D, Liu H, et al. CT-based radiomics analysis of different machine learning models for differentiating benign and malignant parotid tumors. Eur Radiol. 2022;32:6953–64.CrossRefPubMed Zheng Y, Zhou D, Liu H, et al. CT-based radiomics analysis of different machine learning models for differentiating benign and malignant parotid tumors. Eur Radiol. 2022;32:6953–64.CrossRefPubMed
22.
go back to reference Gu D, Xie Y, Wei J, et al. MRI-based radiomics signature: a potential biomarker for identifying glypican 3-positive hepatocellular carcinoma. J Magnet Resonance Imaging JMRI. 2020;52:1679–87.CrossRefPubMed Gu D, Xie Y, Wei J, et al. MRI-based radiomics signature: a potential biomarker for identifying glypican 3-positive hepatocellular carcinoma. J Magnet Resonance Imaging JMRI. 2020;52:1679–87.CrossRefPubMed
24.
go back to reference Lin Z, Wang T, Li Q, et al. Development and validation of MRI-based radiomics model to predict recurrence risk in patients with endometrial cancer: a multicenter study. Eur Radiol. 2023;33:5814–24.CrossRefPubMed Lin Z, Wang T, Li Q, et al. Development and validation of MRI-based radiomics model to predict recurrence risk in patients with endometrial cancer: a multicenter study. Eur Radiol. 2023;33:5814–24.CrossRefPubMed
25.
go back to reference Xu L, Yang P, Liang W, et al. A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma. Theranostics. 2019;9:5374–85.CrossRefPubMedPubMedCentral Xu L, Yang P, Liang W, et al. A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma. Theranostics. 2019;9:5374–85.CrossRefPubMedPubMedCentral
26.
go back to reference Huang Y, Zhu T, Zhang X, et al. Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study. EClinicalMedicine. 2023;58: 101899.CrossRefPubMedPubMedCentral Huang Y, Zhu T, Zhang X, et al. Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study. EClinicalMedicine. 2023;58: 101899.CrossRefPubMedPubMedCentral
27.
go back to reference Lefebvre TL, Ueno Y, Dohan A, et al. Development and validation of multiparametric MRI-based radiomics models for preoperative risk stratification of endometrial cancer. Radiology. 2022;305:375–86.CrossRefPubMed Lefebvre TL, Ueno Y, Dohan A, et al. Development and validation of multiparametric MRI-based radiomics models for preoperative risk stratification of endometrial cancer. Radiology. 2022;305:375–86.CrossRefPubMed
28.
go back to reference Ma X, Gong J, Hu F, et al. Pretreatment multiparametric MRI-based radiomics analysis for the diagnosis of breast phyllodes tumors. J Magnet Resonan Imag JMRI. 2023;57:633–45.CrossRef Ma X, Gong J, Hu F, et al. Pretreatment multiparametric MRI-based radiomics analysis for the diagnosis of breast phyllodes tumors. J Magnet Resonan Imag JMRI. 2023;57:633–45.CrossRef
29.
go back to reference Tamada T, Kido A, Yamamoto A, et al. Comparison of biparametric and multiparametric MRI for clinically significant prostate cancer detection With PI-RADS version 2.1. J Magnetic Resonance Imaging JMRI. 2021;53:283–91.CrossRefPubMed Tamada T, Kido A, Yamamoto A, et al. Comparison of biparametric and multiparametric MRI for clinically significant prostate cancer detection With PI-RADS version 2.1. J Magnetic Resonance Imaging JMRI. 2021;53:283–91.CrossRefPubMed
30.
go back to reference Russo F, Mazzetti S, Regge D, et al. Diagnostic accuracy of single-plane biparametric and multiparametric magnetic resonance imaging in prostate cancer: a randomized noninferiority trial in biopsy-naïve men. Eur Urol Oncol. 2021;4:855–62.CrossRefPubMed Russo F, Mazzetti S, Regge D, et al. Diagnostic accuracy of single-plane biparametric and multiparametric magnetic resonance imaging in prostate cancer: a randomized noninferiority trial in biopsy-naïve men. Eur Urol Oncol. 2021;4:855–62.CrossRefPubMed
31.
go back to reference Lee SS, Cheah YK. The interplay between microRNAs and cellular components of tumour microenvironment (TME) on non-small-cell lung cancer (NSCLC) progression. J Immunol Res. 2019;2019:3046379.CrossRefPubMedPubMedCentral Lee SS, Cheah YK. The interplay between microRNAs and cellular components of tumour microenvironment (TME) on non-small-cell lung cancer (NSCLC) progression. J Immunol Res. 2019;2019:3046379.CrossRefPubMedPubMedCentral
33.
go back to reference Han C, Ma S, Liu X, et al. Radiomics models based on apparent diffusion coefficient maps for the prediction of high-grade prostate cancer at radical prostatectomy: comparison with preoperative biopsy. J Magnetic Resonan Imag : JMRI. 2021;54:1892–901.CrossRef Han C, Ma S, Liu X, et al. Radiomics models based on apparent diffusion coefficient maps for the prediction of high-grade prostate cancer at radical prostatectomy: comparison with preoperative biopsy. J Magnetic Resonan Imag : JMRI. 2021;54:1892–901.CrossRef
34.
go back to reference Zhou C, Zhang YF, Guo S, et al. Multiparametric MRI radiomics in prostate cancer for predicting Ki-67 expression and Gleason score: a multicenter retrospective study. Discov Oncol. 2023;14:133.CrossRefPubMedPubMedCentral Zhou C, Zhang YF, Guo S, et al. Multiparametric MRI radiomics in prostate cancer for predicting Ki-67 expression and Gleason score: a multicenter retrospective study. Discov Oncol. 2023;14:133.CrossRefPubMedPubMedCentral
Metadata
Title
Prediction of prostate cancer aggressiveness using magnetic resonance imaging radiomics: a dual-center study
Authors
Nini Pan
Liuyan Shi
Diliang He
Jianxin Zhao
Lianqiu Xiong
Lili Ma
Jing Li
Kai Ai
Lianping Zhao
Gang Huang
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-00980-8

Other articles of this Issue 1/2024

Discover Oncology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine